Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584459 | 1.00 | KCNH2 (0.49) | KCNH2ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL4583955 | 0.85 | KMT2A (0.54) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL4583951 | 0.85 | KMT2A (0.54) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL4585449 | 0.84 | MEN1 (0.57) | LMNAMEN1KMT2A | |
| SCHEMBL4585446 | 0.84 | MEN1 (0.57) | LMNAMEN1KMT2A | |
| SCHEMBL1680543 | 0.79 | ALDH1A1 (0.51) | ALDH1A1LMNASMN1; SMN2GAAMAPT | |
| SCHEMBL1989446 | 0.77 | ALDH1A1 (0.49) | ALDH1A1LMNASMN1; SMN2GAAMAPT | |
| SCHEMBL4585162 | 0.76 | MEN1 (0.50) | MEN1KMT2A | |
| SCHEMBL4585166 | 0.76 | MEN1 (0.50) | MEN1KMT2A | |
| SCHEMBL4585246 | 0.75 | DRD2 (0.53) | KCNH2ALDH1A1ACHESLC6A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | KCNH2 172/4885ALDH1A1 1621/4885LMNA 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.